Jingwei Hengrun (688326.SH) controlling shareholder proposes the company to repurchase 100 million to 200 million yuan of shares for future sale.
Jingwei Hengrun (688326.SH) announced that on January 10, 2025, the company's board of directors received a company controller...
Jingwei Hengrun (688326.SH) announced that the board of directors received a proposal from the company's controlling shareholder, actual controller, chairman and general manager Ji Yingcun on January 10, 2025, regarding the proposal for Beijing Jingwei Hengrun Technology Co., Ltd. to repurchase the company's shares. Ji Yingcun proposed that the company use its own funds, self-raised funds, and stock repurchase special loans provided by the Tianjin Branch of Shanghai Pudong Development Bank to repurchase some of the RMB ordinary shares (A shares) issued by the company through the Shanghai Stock Exchange trading system in a centralized competitive bidding manner, for the purpose of maintaining the company's value and shareholders' equity.
The price for this share repurchase shall not exceed RMB 130 per share (including the principal), and the total amount of funds for this share repurchase shall not be less than RMB 100 million (including the principal), and not exceed RMB 200 million (including the principal). This share repurchase is based on the purpose of maintaining the company's value and shareholders' equity. The repurchased shares will be sold in a centralized competitive bidding manner 12 months after the disclosure of the results of the share repurchase and changes in shareholding, and the sale will be completed within 3 years after the disclosure of the results of the share repurchase and changes in shareholding. The term of the share repurchase shall be within 3 months from the date of approval by the board of directors of this share repurchase plan.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025